Vitexin, on the other hand, is shown to improve insulin signalling in non-alcoholic fatty liver disease (NAFLD) mice through upregulation of insulin receptor substrate-1 (IRS-1) and also its downstream target AKT [29]. The gene discussed is AKT1; the disease is metabolic dysfunction-associated steatotic liver disease.